Digital medical technology company Brainlab has acquired Mint Medical, a developer of image reading and reporting software for clinical routine and research, for an undisclosed amount.
With this deal, Brainlab intends to boost the structured diagnosis, analysis, and treatment of cancer and other diseases to meet the requirements of personalised treatments.
Mint Medical’s software helps in the diagnostic process. Due to the technology-enabled, context-sensitive approach of radiological reporting, the gap between the image and the diagnostic report is bridged, providing a structured and holistic picture of the individual patient’s situation and clinical history.
Brainlab president and CEO Stefan Vilsmeier said: “The transformation of our health care system is currently focused in large part on standardising clinical data through a coding system.
“However high quality and consistency of such data requires a validated, reproducible, and structured digital process, for which Mint Medical is setting the benchmark.”
The merged entity will provide existing customers of Mint with the ability to connect data across several oncological subspecialties, right from clinical oncology to surgical oncology and radiotherapy.
On integrating patient-reported outcomes measures (PROMs) from a Brainlab company, VisionTree, valuable longitudinal data will become available to the pool for analysis.
Radiology users of Mint Medical will stand to benefit from Brainlab’s expertise in deep integration with a wide spectrum of standards such as DICOM, FHIR, HL7 and within hospital information systems (HIS).
These users will also benefit from additional process automation by deriving pre-existing data to prefill some fields in the structured clinical forms.
Additional automation becomes possible with the addition of Brainlab Anatomical Mapping and context-based AI algorithms. Information is drawn automatically from diagnostic images, thereby more efficiently connecting image data with the structured templates.
Mint Medical president Matthias Baumhauer said: “Brainlab brings to Mint a highly compatible entrepreneurial culture, enabling us to more rapidly enhance, scale, and deploy our technology. We are excited about the tremendous opportunities for both our clinical research and clinical routine users”.
With the deal, the Brainlab oncology portfolio gets bolstered by frontloading the treatment planning process with more structured, detailed, and clinically relevant information.
At tumour board meetings, participants will be able to access standardised reports on radiological findings to support their discussion on treatment decisions specific to patients.
Following treatment, by integrating data from oncology and radiology, the follow-up process gets enhanced through a systematic response assessment.
Structured radiological reports will enable software-driven comparison, which in turn will allow independent validation through several experts, either in the context of a clinical trial or for quality assurance.
Clinical trial users of Mint Medical will benefit from Brainlab technology in terms of cloud computing, image data analysis, and patient-reported outcomes measures.
The merged entity intends to boost the technological infrastructure for managing clinical trials besides large scale registries.